MarketCap
Facebook
X
Telegram
Reviva Pharmaceuticals Holdings Balance Sheet 2025-2011 | RVPH
Brief overview of Reviva Pharmaceuticals Holdings's assets and capital
This overview follows the five latest available annual observations between 2021 and 2025.
The asset base decreased -49.3%, from $31.4 million to $15.9 million. Resources became smaller over the five periods.
Asset growth of -49.3% came with a +167.7% rise in liabilities. Financial leverage became more prominent.
Equity funds 54.3% of assets versus 91.3% initially. This creates a conservative balance sheet structure.
The cash share moved from 94.5% to 90.7%. A higher figure generally provides more room in an adverse scenario.
The balance sheet includes a negative accumulated result of -$184.1 million. It should be assessed alongside historical profits and capital distributions.
Balance sheet takeaway
Reviva Pharmaceuticals Holdings has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.
Annual Balance Sheet Reviva Pharmaceuticals Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -8.76 M | 3.76 M | - | - | - | - | - | - | - | - |
Total Current Liabilities |
7.28 M | 14.6 M | 17.2 M | 9.96 M | 2.34 M | 300 K | 23 K | - | - | - | - | - | - | - | - |
Total Liabilities |
7.28 M | 14.7 M | 18 M | 10.5 M | 2.72 M | 1.33 M | 6.81 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-184 M | -164 M | -134 M | -95.1 M | -66.8 M | - | -54.5 M | - | - | - | - | - | - | - | - |
Total Assets |
15.9 M | 15.5 M | 23.7 M | 18.9 M | 31.4 M | 8.76 M | 2.6 K | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
14.4 M | 13.5 M | 23.4 M | 18.5 M | 29.7 M | 8.76 M | 193 | - | - | - | - | - | - | - | - |
Book Value |
8.65 M | 813 K | 5.72 M | 8.39 M | 28.7 M | 7.43 M | -6.81 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
8.65 M | 813 K | 5.72 M | 8.39 M | 28.7 M | 5.47 M | -6.81 M | -5.96 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Reviva Pharmaceuticals Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Liabilities |
7.28 M | 6.12 M | 14.7 M | 9.78 M | 12.1 M | 11.5 M | 14.7 M | 17.6 M | 14.1 M | 14.8 M | 18 M | 13.9 M | 10.2 M | 7.12 M | 6.61 M | 3.68 M | 4.58 M | 3.91 M | 2.72 M | 1.62 M | 2.01 M | 2.14 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 6.81 M | 2.25 M | 2.24 M | 2.24 M | 2.24 M | 2.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-184 M | -187 M | -164 M | -181 M | -177 M | -171 M | -164 M | -158 M | -150 M | -142 M | -134 M | -121 M | -110 M | -97.8 M | -91.2 M | -83.1 M | -79.5 M | -74.2 M | -66.8 M | -63.1 M | -60.9 M | -59.3 M | -58.3 M | -58.3 M | -58.3 M | -58.3 M | -54.5 M | 1.19 M | 913 K | 574 K | 268 K | 4.35 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
15.9 M | 23.6 M | 15.5 M | 14.3 M | 11.6 M | 7.08 M | 15.5 M | 7.63 M | 8.05 M | 13.5 M | 23.7 M | 5.39 M | 11.8 M | 12.9 M | 18.9 M | 24 M | 20.6 M | 25.3 M | 31.4 M | 33.9 M | 36.5 M | 6.66 M | 8.76 M | 8.76 M | 8.76 M | 8.76 M | 2.6 K | 66.3 M | 66 M | 65.6 M | 65.3 M | 65.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.9 M | 22.2 M | 14.4 M | 13.2 M | 10.4 M | 5.29 M | 13.5 M | 5.56 M | 6.18 M | 12 M | 23.4 M | 4.97 M | 11.2 M | 11.3 M | 18.5 M | 23.2 M | 19.4 M | 23.4 M | 29.7 M | 33.5 M | 35.8 M | 5.64 M | 8.76 M | 8.76 M | 8.76 M | 8.76 M | 193 | 211 K | 274 K | 313 K | 401 K | 211 K | 442 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
8.65 M | 17.4 M | 813 K | 4.55 M | -459 K | -4.46 M | 813 K | -9.98 M | -6.04 M | -1.35 M | 5.72 M | -8.52 M | 1.62 M | 5.78 M | 12.3 M | 20.4 M | 16.1 M | 21.4 M | 28.7 M | 32.3 M | 34.5 M | 4.52 M | 5.47 M | 5.47 M | 5.47 M | 5.47 M | -6.81 M | 64 M | 63.7 M | 63.4 M | 63.1 M | 62.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
813 K | 17.4 M | 5.72 M | 4.55 M | -459 K | -4.46 M | 813 K | -9.98 M | -6.04 M | -1.35 M | 5.72 M | -12.8 M | -1.82 M | 1.61 M | 12.3 M | 20.4 M | 16.1 M | 21.4 M | 28.7 M | 32.3 M | 34.5 M | 4.52 M | 5.47 M | 5.47 M | 5.47 M | 5.47 M | -6.81 M | 5 M | 5 M | 5 M | -5.96 M | 5 M | 5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Reviva Pharmaceuticals Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.